Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291904 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL8744067 | 0.92 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL8065083 | 0.86 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL10558853 | 0.86 | TSHR (0.47) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL12603011 | 0.85 | GPR35 (0.53) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL27081346 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL6136028 | 0.85 | TSHR (0.49) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL29891185 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL8066780 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL10536923 | 0.81 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1016405-A2 | Arylating medicaments | Radopath Pharmaceuticals International Limited (GB) | 2000-07-05 | — | — | EP | claimed |
| EP-0751768-A1 | ANTI-VIRAL AND ANTI-CANCER AGENTS | RADOPATH LIMITED (GB) | 1997-01-08 | — | — | EP | claimed |
| CN-1124012-A | Arylating medicaments | RADOPATH LTD (GB) | 1996-06-05 | — | — | CN | claimed |
| EP-0700287-A1 | ARYLATING MEDICAMENTS | RADOPATH LIMITED (GB) | 1996-03-13 | — | — | EP | claimed |
| EP-0677292-A1 | Anti-viral and anti-cancer agents | RADOPATH LIMITED (GB) | 1995-10-18 | — | — | EP | claimed |
| WO-1995024897-A1 | ANTI-VIRAL AND ANTI-CANCER AGENTS | RADOPATH LIMITED (GB) | 1995-09-21 | — | — | WO | claimed |
| WO-1994027584-A2 | ARYLATING MEDICAMENTS | RADOPATH LIMITED (GB) | 1994-12-08 | — | — | WO | claimed |
| US-20110171267-A1 | ANTI-FUNGAL COMPOSITION | Immunitor USA, Inc. | 2011-07-14 | — | — | US | disclosed |
| US-7914799-B2 | Vaccine; heat deactivated antigen; induce immunology response | Immunitor USA, Inc. (US) | 2011-03-29 | — | — | US | disclosed |
| US-4169153-A | PROPHYLAXIS, ANTIHISTAMINES | THE UPJOHN COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-4091011-A | PROPHYLACTIC ANTIANAPHYLACTICS, ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | ALDH1A1 1569/4885CYP1A2 1066/4885CYP2D6 1222/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | ALDH1A1 1723/4885CYP1A2 968/4885CYP2D6 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.